How to Improve Healthcare for Patients with Multimorbidity and Polypharmacy in Primary Care: A Pragmatic Cluster-Randomized Clinical Trial of the MULTIPAP Intervention release_rtmwxinarjdbtghv546zhnkv4q

by Isabel Cura-Gonzalez, Juan A. López-Rodríguez, Leiva-Fernández F, Antonio Gimeno-Miguel, Beatriz Poblador-Plou, Fernando López Verde, Cristina Lozano-Hernández, Victoria Pico-Soler, Ma Josefa Bujalance-Zafra, Luis A. Gimeno-Feliu, Mercedes Aza, Marisa Rogero-Blanco (+13 others)

Published in Journal of Personalized Medicine by MDPI AG.

2022   Volume 12, Issue 5, p752

Abstract

(1) Purpose: To investigate a complex MULTIPAP intervention that implements the Ariadne principles in a primary care population of young-elderly patients with multimorbidity and polypharmacy and to evaluate its effectiveness for improving the appropriateness of prescriptions. (2) Methods: A pragmatic cluster-randomized clinical trial was conducted involving 38 family practices in Spain. Patients aged 65–74 years with multimorbidity and polypharmacy were recruited. Family physicians (FPs) were randomly allocated to continue usual care or to provide the MULTIPAP intervention based on the Ariadne principles with two components: FP training (eMULTIPAP) and FP patient interviews. The primary outcome was the appropriateness of prescribing, measured as the between-group difference in the mean Medication Appropriateness Index (MAI) score change from the baseline to the 6-month follow-up. The secondary outcomes were quality of life (EQ-5D-5 L), patient perceptions of shared decision making (collaboRATE), use of health services, treatment adherence, and incidence of drug adverse events (all at 1 year), using multi-level regression models, with FP as a random effect. (3) Results: We recruited 117 FPs and 593 of their patients. In the intention-to-treat analysis, the between-group difference for the mean MAI score change after a 6-month follow-up was −2.42 (95% CI from −4.27 to −0.59) and, between baseline and a 12-month follow-up was −3.40 (95% CI from −5.45 to −1.34). There were no significant differences in any other secondary outcomes. (4) Conclusions: The MULTIPAP intervention improved medication appropriateness sustainably over the follow-up time. The small magnitude of the effect, however, advises caution in the interpretation of the results given the paucity of evidence for the clinical benefit of the observed change in the MAI. Trial registration: Clinicaltrials.gov NCT02866799.
In application/xml+jats format

Archived Files and Locations

application/pdf   536.7 kB
file_ynnx7gnv2jde3ftwz7cajsz7qa
mdpi-res.com (publisher)
web.archive.org (webarchive)
application/pdf   719.4 kB
file_jd456xbe6fhb7assqhqwwohs7e
mdpi-res.com (web)
web.archive.org (webarchive)

Web Captures

https://www.mdpi.com/2075-4426/12/5/752/htm
2022-06-08 20:42:02 | 38 resources
webcapture_5ex2z2x4pbeuhn5rnzetdxl6dm
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2022-05-06
Language   en ?
DOI  10.3390/jpm12050752
PubMed  35629175
PMC  PMC9144280
Journal Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  2075-4426
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 5c03689f-c897-4784-a832-b751b5e30c65
API URL: JSON